 | • レポートコード：MRC2Q12-16833 • 出版社/出版日：QYResearch / 2022年12月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、111ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥710,500 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,421,000 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、旅行者下痢症予防治療のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 旅行者下痢症予防治療のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 旅行者下痢症予防治療の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 旅行者下痢症予防治療のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの旅行者下痢症予防治療の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の旅行者下痢症予防治療の売上および2028年までの予測に焦点を当てています。 旅行者下痢症予防治療のグローバル主要企業には、Bayer AG、Johnson & Johnson、Merck & Co., Inc.、Novartis AG、Pfizer Inc.、Sanofi、GlaxoSmithKline plc、AstraZeneca、Bristol-Myers Squibb Company、Allergen Plc. Etc.などがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 旅行者下痢症予防治療市場は、タイプとアプリケーションによって区分されます。世界の旅行者下痢症予防治療市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 抗菌薬、抗生物質、止瀉薬、電解質 【アプリケーション別セグメント】 病院 薬局、小売薬局、ドラッグストア、一次医療センター 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 旅行者下痢症予防治療製品概要 - タイプ別市場（抗菌薬、抗生物質、止瀉薬、電解質） - アプリケーション別市場（病院 薬局、小売薬局、ドラッグストア、一次医療センター） - 調査の目的 ・エグゼクティブサマリー - 世界の旅行者下痢症予防治療販売量予測2017-2028 - 世界の旅行者下痢症予防治療売上予測2017-2028 - 旅行者下痢症予防治療の地域別販売量 - 旅行者下痢症予防治療の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別旅行者下痢症予防治療販売量 - 主要メーカー別旅行者下痢症予防治療売上 - 主要メーカー別旅行者下痢症予防治療価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（抗菌薬、抗生物質、止瀉薬、電解質） - 旅行者下痢症予防治療のタイプ別販売量 - 旅行者下痢症予防治療のタイプ別売上 - 旅行者下痢症予防治療のタイプ別価格 ・アプリケーション別市場規模（病院 薬局、小売薬局、ドラッグストア、一次医療センター） - 旅行者下痢症予防治療のアプリケーション別販売量 - 旅行者下痢症予防治療のアプリケーション別売上 - 旅行者下痢症予防治療のアプリケーション別価格 ・北米市場 - 北米の旅行者下痢症予防治療市場規模（タイプ別、アプリケーション別） - 主要国別の旅行者下痢症予防治療市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの旅行者下痢症予防治療市場規模（タイプ別、アプリケーション別） - 主要国別の旅行者下痢症予防治療市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の旅行者下痢症予防治療市場規模（タイプ別、アプリケーション別） - 主要国別の旅行者下痢症予防治療市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の旅行者下痢症予防治療市場規模（タイプ別、アプリケーション別） - 主要国別の旅行者下痢症予防治療市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの旅行者下痢症予防治療市場規模（タイプ別、アプリケーション別） - 主要国別の旅行者下痢症予防治療市場規模（トルコ、サウジアラビア） ・企業情報 Bayer AG、Johnson & Johnson、Merck & Co., Inc.、Novartis AG、Pfizer Inc.、Sanofi、GlaxoSmithKline plc、AstraZeneca、Bristol-Myers Squibb Company、Allergen Plc. Etc. ・産業チェーン及び販売チャネル分析 - 旅行者下痢症予防治療の産業チェーン分析 - 旅行者下痢症予防治療の原材料 - 旅行者下痢症予防治療の生産プロセス - 旅行者下痢症予防治療の販売及びマーケティング - 旅行者下痢症予防治療の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 旅行者下痢症予防治療の産業動向 - 旅行者下痢症予防治療のマーケットドライバー - 旅行者下痢症予防治療の課題 - 旅行者下痢症予防治療の阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Prophylactic Traveler’s Diarrhea Treatment estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Prophylactic Traveler’s Diarrhea Treatment is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Prophylactic Traveler’s Diarrhea Treatment is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Prophylactic Traveler’s Diarrhea Treatment is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Prophylactic Traveler’s Diarrhea Treatment include Bayer AG, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, GlaxoSmithKline plc, AstraZeneca and Bristol-Myers Squibb Company, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Prophylactic Traveler’s Diarrhea Treatment companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Prophylactic Traveler’s Diarrhea Treatment market. Further, it explains the major drivers and regional dynamics of the global Prophylactic Traveler’s Diarrhea Treatment market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Bayer AG
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Sanofi
GlaxoSmithKline plc
AstraZeneca
Bristol-Myers Squibb Company
Allergen Plc. Etc.
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Prophylactic Traveler’s Diarrhea Treatment Segment by Type
Antimicrobials
Antibiotics
Anti-Diarrheal
Electrolytes
Prophylactic Traveler’s Diarrhea Treatment Segment by Application
Hospitals Pharmacy
Retail Pharmacy
Drug Store
Primary Healthcare Centers
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Prophylactic Traveler’s Diarrhea Treatment market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Prophylactic Traveler’s Diarrhea Treatment market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Prophylactic Traveler’s Diarrhea Treatment, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Prophylactic Traveler’s Diarrhea Treatment, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Prophylactic Traveler’s Diarrhea Treatment revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Prophylactic Traveler’s Diarrhea Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Prophylactic Traveler’s Diarrhea Treatment revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Bayer AG, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, GlaxoSmithKline plc, AstraZeneca and Bristol-Myers Squibb Company, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Prophylactic Traveler’s Diarrhea Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Prophylactic Traveler’s Diarrhea Treatment companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Prophylactic Traveler’s Diarrhea Treatment revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Prophylactic Traveler’s Diarrhea Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Antimicrobials
1.2.3 Antibiotics
1.2.4 Anti-Diarrheal
1.2.5 Electrolytes
1.3 Market by Application
1.3.1 Global Prophylactic Traveler’s Diarrhea Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Drug Store
1.3.5 Primary Healthcare Centers
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Prophylactic Traveler’s Diarrhea Treatment Market Perspective (2017-2028)
2.2 Prophylactic Traveler’s Diarrhea Treatment Growth Trends by Region
2.2.1 Prophylactic Traveler’s Diarrhea Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Prophylactic Traveler’s Diarrhea Treatment Historic Market Size by Region (2017-2022)
2.2.3 Prophylactic Traveler’s Diarrhea Treatment Forecasted Market Size by Region (2023-2028)
2.3 Prophylactic Traveler’s Diarrhea Treatment Market Dynamics
2.3.1 Prophylactic Traveler’s Diarrhea Treatment Industry Trends
2.3.2 Prophylactic Traveler’s Diarrhea Treatment Market Drivers
2.3.3 Prophylactic Traveler’s Diarrhea Treatment Market Challenges
2.3.4 Prophylactic Traveler’s Diarrhea Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Prophylactic Traveler’s Diarrhea Treatment Players by Revenue
3.1.1 Global Top Prophylactic Traveler’s Diarrhea Treatment Players by Revenue (2017-2022)
3.1.2 Global Prophylactic Traveler’s Diarrhea Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Prophylactic Traveler’s Diarrhea Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Prophylactic Traveler’s Diarrhea Treatment Revenue
3.4 Global Prophylactic Traveler’s Diarrhea Treatment Market Concentration Ratio
3.4.1 Global Prophylactic Traveler’s Diarrhea Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Prophylactic Traveler’s Diarrhea Treatment Revenue in 2021
3.5 Prophylactic Traveler’s Diarrhea Treatment Key Players Head office and Area Served
3.6 Key Players Prophylactic Traveler’s Diarrhea Treatment Product Solution and Service
3.7 Date of Enter into Prophylactic Traveler’s Diarrhea Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Prophylactic Traveler’s Diarrhea Treatment Breakdown Data by Type
4.1 Global Prophylactic Traveler’s Diarrhea Treatment Historic Market Size by Type (2017-2022)
4.2 Global Prophylactic Traveler’s Diarrhea Treatment Forecasted Market Size by Type (2023-2028)
5 Prophylactic Traveler’s Diarrhea Treatment Breakdown Data by Application
5.1 Global Prophylactic Traveler’s Diarrhea Treatment Historic Market Size by Application (2017-2022)
5.2 Global Prophylactic Traveler’s Diarrhea Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Prophylactic Traveler’s Diarrhea Treatment Market Size (2017-2028)
6.2 North America Prophylactic Traveler’s Diarrhea Treatment Market Size by Type
6.2.1 North America Prophylactic Traveler’s Diarrhea Treatment Market Size by Type (2017-2022)
6.2.2 North America Prophylactic Traveler’s Diarrhea Treatment Market Size by Type (2023-2028)
6.2.3 North America Prophylactic Traveler’s Diarrhea Treatment Market Share by Type (2017-2028)
6.3 North America Prophylactic Traveler’s Diarrhea Treatment Market Size by Application
6.3.1 North America Prophylactic Traveler’s Diarrhea Treatment Market Size by Application (2017-2022)
6.3.2 North America Prophylactic Traveler’s Diarrhea Treatment Market Size by Application (2023-2028)
6.3.3 North America Prophylactic Traveler’s Diarrhea Treatment Market Share by Application (2017-2028)
6.4 North America Prophylactic Traveler’s Diarrhea Treatment Market Size by Country
6.4.1 North America Prophylactic Traveler’s Diarrhea Treatment Market Size by Country (2017-2022)
6.4.2 North America Prophylactic Traveler’s Diarrhea Treatment Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Prophylactic Traveler’s Diarrhea Treatment Market Size (2017-2028)
7.2 Europe Prophylactic Traveler’s Diarrhea Treatment Market Size by Type
7.2.1 Europe Prophylactic Traveler’s Diarrhea Treatment Market Size by Type (2017-2022)
7.2.2 Europe Prophylactic Traveler’s Diarrhea Treatment Market Size by Type (2023-2028)
7.2.3 Europe Prophylactic Traveler’s Diarrhea Treatment Market Share by Type (2017-2028)
7.3 Europe Prophylactic Traveler’s Diarrhea Treatment Market Size by Application
7.3.1 Europe Prophylactic Traveler’s Diarrhea Treatment Market Size by Application (2017-2022)
7.3.2 Europe Prophylactic Traveler’s Diarrhea Treatment Market Size by Application (2023-2028)
7.3.3 Europe Prophylactic Traveler’s Diarrhea Treatment Market Share by Application (2017-2028)
7.4 Europe Prophylactic Traveler’s Diarrhea Treatment Market Size by Country
7.4.1 Europe Prophylactic Traveler’s Diarrhea Treatment Market Size by Country (2017-2022)
7.4.2 Europe Prophylactic Traveler’s Diarrhea Treatment Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Prophylactic Traveler’s Diarrhea Treatment Market Size (2017-2028)
8.2 Asia-Pacific Prophylactic Traveler’s Diarrhea Treatment Market Size by Type
8.2.1 Asia-Pacific Prophylactic Traveler’s Diarrhea Treatment Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Prophylactic Traveler’s Diarrhea Treatment Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Prophylactic Traveler’s Diarrhea Treatment Market Share by Type (2017-2028)
8.3 Asia-Pacific Prophylactic Traveler’s Diarrhea Treatment Market Size by Application
8.3.1 Asia-Pacific Prophylactic Traveler’s Diarrhea Treatment Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Prophylactic Traveler’s Diarrhea Treatment Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Prophylactic Traveler’s Diarrhea Treatment Market Share by Application (2017-2028)
8.4 Asia-Pacific Prophylactic Traveler’s Diarrhea Treatment Market Size by Region
8.4.1 Asia-Pacific Prophylactic Traveler’s Diarrhea Treatment Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Prophylactic Traveler’s Diarrhea Treatment Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Prophylactic Traveler’s Diarrhea Treatment Market Size (2017-2028)
9.2 Latin America Prophylactic Traveler’s Diarrhea Treatment Market Size by Type
9.2.1 Latin America Prophylactic Traveler’s Diarrhea Treatment Market Size by Type (2017-2022)
9.2.2 Latin America Prophylactic Traveler’s Diarrhea Treatment Market Size by Type (2023-2028)
9.2.3 Latin America Prophylactic Traveler’s Diarrhea Treatment Market Share by Type (2017-2028)
9.3 Latin America Prophylactic Traveler’s Diarrhea Treatment Market Size by Application
9.3.1 Latin America Prophylactic Traveler’s Diarrhea Treatment Market Size by Application (2017-2022)
9.3.2 Latin America Prophylactic Traveler’s Diarrhea Treatment Market Size by Application (2023-2028)
9.3.3 Latin America Prophylactic Traveler’s Diarrhea Treatment Market Share by Application (2017-2028)
9.4 Latin America Prophylactic Traveler’s Diarrhea Treatment Market Size by Country
9.4.1 Latin America Prophylactic Traveler’s Diarrhea Treatment Market Size by Country (2017-2022)
9.4.2 Latin America Prophylactic Traveler’s Diarrhea Treatment Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Prophylactic Traveler’s Diarrhea Treatment Market Size (2017-2028)
10.2 Middle East & Africa Prophylactic Traveler’s Diarrhea Treatment Market Size by Type
10.2.1 Middle East & Africa Prophylactic Traveler’s Diarrhea Treatment Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Prophylactic Traveler’s Diarrhea Treatment Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Prophylactic Traveler’s Diarrhea Treatment Market Share by Type (2017-2028)
10.3 Middle East & Africa Prophylactic Traveler’s Diarrhea Treatment Market Size by Application
10.3.1 Middle East & Africa Prophylactic Traveler’s Diarrhea Treatment Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Prophylactic Traveler’s Diarrhea Treatment Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Prophylactic Traveler’s Diarrhea Treatment Market Share by Application (2017-2028)
10.4 Middle East & Africa Prophylactic Traveler’s Diarrhea Treatment Market Size by Country
10.4.1 Middle East & Africa Prophylactic Traveler’s Diarrhea Treatment Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Prophylactic Traveler’s Diarrhea Treatment Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Bayer AG
11.1.1 Bayer AG Company Details
11.1.2 Bayer AG Business Overview
11.1.3 Bayer AG Prophylactic Traveler’s Diarrhea Treatment Introduction
11.1.4 Bayer AG Revenue in Prophylactic Traveler’s Diarrhea Treatment Business (2017-2022)
11.1.5 Bayer AG Recent Developments
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Details
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Prophylactic Traveler’s Diarrhea Treatment Introduction
11.2.4 Johnson & Johnson Revenue in Prophylactic Traveler’s Diarrhea Treatment Business (2017-2022)
11.2.5 Johnson & Johnson Recent Developments
11.3 Merck & Co., Inc.
11.3.1 Merck & Co., Inc. Company Details
11.3.2 Merck & Co., Inc. Business Overview
11.3.3 Merck & Co., Inc. Prophylactic Traveler’s Diarrhea Treatment Introduction
11.3.4 Merck & Co., Inc. Revenue in Prophylactic Traveler’s Diarrhea Treatment Business (2017-2022)
11.3.5 Merck & Co., Inc. Recent Developments
11.4 Novartis AG
11.4.1 Novartis AG Company Details
11.4.2 Novartis AG Business Overview
11.4.3 Novartis AG Prophylactic Traveler’s Diarrhea Treatment Introduction
11.4.4 Novartis AG Revenue in Prophylactic Traveler’s Diarrhea Treatment Business (2017-2022)
11.4.5 Novartis AG Recent Developments
11.5 Pfizer Inc.
11.5.1 Pfizer Inc. Company Details
11.5.2 Pfizer Inc. Business Overview
11.5.3 Pfizer Inc. Prophylactic Traveler’s Diarrhea Treatment Introduction
11.5.4 Pfizer Inc. Revenue in Prophylactic Traveler’s Diarrhea Treatment Business (2017-2022)
11.5.5 Pfizer Inc. Recent Developments
11.6 Sanofi
11.6.1 Sanofi Company Details
11.6.2 Sanofi Business Overview
11.6.3 Sanofi Prophylactic Traveler’s Diarrhea Treatment Introduction
11.6.4 Sanofi Revenue in Prophylactic Traveler’s Diarrhea Treatment Business (2017-2022)
11.6.5 Sanofi Recent Developments
11.7 GlaxoSmithKline plc
11.7.1 GlaxoSmithKline plc Company Details
11.7.2 GlaxoSmithKline plc Business Overview
11.7.3 GlaxoSmithKline plc Prophylactic Traveler’s Diarrhea Treatment Introduction
11.7.4 GlaxoSmithKline plc Revenue in Prophylactic Traveler’s Diarrhea Treatment Business (2017-2022)
11.7.5 GlaxoSmithKline plc Recent Developments
11.8 AstraZeneca
11.8.1 AstraZeneca Company Details
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Prophylactic Traveler’s Diarrhea Treatment Introduction
11.8.4 AstraZeneca Revenue in Prophylactic Traveler’s Diarrhea Treatment Business (2017-2022)
11.8.5 AstraZeneca Recent Developments
11.9 Bristol-Myers Squibb Company
11.9.1 Bristol-Myers Squibb Company Company Details
11.9.2 Bristol-Myers Squibb Company Business Overview
11.9.3 Bristol-Myers Squibb Company Prophylactic Traveler’s Diarrhea Treatment Introduction
11.9.4 Bristol-Myers Squibb Company Revenue in Prophylactic Traveler’s Diarrhea Treatment Business (2017-2022)
11.9.5 Bristol-Myers Squibb Company Recent Developments
11.10 Allergen Plc. Etc.
11.10.1 Allergen Plc. Etc. Company Details
11.10.2 Allergen Plc. Etc. Business Overview
11.10.3 Allergen Plc. Etc. Prophylactic Traveler’s Diarrhea Treatment Introduction
11.10.4 Allergen Plc. Etc. Revenue in Prophylactic Traveler’s Diarrhea Treatment Business (2017-2022)
11.10.5 Allergen Plc. Etc. Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
| 【旅行者下痢症予防治療について】 旅行者下痢症は、旅行者が新しい環境で食事や水分を摂取した際に発生する下痢で、その原因は主に感染症によるものです。特に発展途上国や衛生状態が不十分な地域に旅行すると、様々な病原体にさらされるリスクが高くなります。旅行者下痢症の予防と治療は、旅行をより快適で安全なものにするための重要な要素です。 旅行者下痢症は、主に細菌、ウイルス、寄生虫の感染によって引き起こされます。最も一般的な原因としては、大腸菌（特にエンテロトキシゲニック大腸菌）、サルモネラ、シゲラ、ノロウイルス、ロタウイルスなどが知られています。これらの病原体は、汚染された飲食物や水を通じて人体に侵入し、消化器系に影響を及ぼします。 旅行者下痢症の特徴として、急に発症する腹痛、下痢、場合によっては発熱や吐き気が伴うことが挙げられます。この症状は通常、旅行開始から数日以内に現れ、数日から一週間程度で自然に回復することが一般的です。しかし、脱水症状や電解質異常を引き起こすことがあり、特に高齢者や免疫力が低下している人にとっては重篤な状態を招く可能性もあります。 旅行者下痢症の予防にはいくつかのアプローチがあります。まず第一に、衛生的な食事と水の選択が重要です。生水や氷、食べたことのない生鮮食品（特に生野菜や未加熱のシーフード）は避けるべきです。また、食べ物は十分に加熱されていることを確認し、信頼できる飲食店を選ぶことが推奨されます。手洗いも予防には欠かせない要素であり、衛生的な習慣を持つことが感染症のリスクを低下させます。 また、旅行者下痢症に対する予防的な治療として、抗生物質の嘱託も存在します。特に高リスクな地域に旅行する場合、一部の旅行者に対しては事前に抗生物質を処方されることがありますが、これは医師の判断によるものです。これにより、症状が発生する前に病原菌に対抗することが可能です。しかし、抗生物質の使用には副作用や抵抗性の問題もあるため、合理的な判断が求められます。 また、旅先での症状緩和のためにオフラクトースを含む下痢止め薬が用いられることもあります。これにより、腸内の水分バランスを保ち、脱水を予防することができます。ただし、下痢の原因が細菌感染の場合、抗生物質を使用しない限り、感染は解消されないことに注意が必要です。 旅行者下痢症の研究分野では、新しい技術やアプローチが開発されています。例えば、ワクチン開発が進められており、特にエンテロトキシゲニック大腸菌に対するワクチンが注目されています。これが実用化されれば、旅行者下痢症の発症率を大幅に減少させることが期待されています。 さらに、腸内フローラに着目した研究も進行中です。腸内の健康を保つことで、免疫力を高め、感染症に対する耐性を強化することが可能であるとの見解が広がっています。プロバイオティクスやプレバイオティクスを用いることで、腸内環境を整えることが提案されています。 旅行者下痢症の予防には、個々の旅行者の知識と行動が不可欠です。適切な情報を持ち、リスクを理解し、実行可能な予防策を講じることが、旅行を安全に楽しむための鍵となります。旅行者自身が持つべき意識と責任は、全員が快適に旅行を楽しむために重要です。 旅行者下痢症は、他人に感染を広げる可能性があるため、旅行中に症状が発生した場合は速やかに医療機関を受診することが大切です。また、自身の症状に気づいた場合は、同行者や他の旅行者に感染が広がらないように注意が必要です。 最終的に、旅行者下痢症の予防と治療は、旅行者自身の行動、医療の進展、地域の衛生環境の向上が組み合わさることによって初めて効果的になる要素といえるでしょう。この領域における理解を深め、適切な対策を講じることで、安心して旅行を楽しむことができるようになります。旅行を計画する際には、事前に予防策についての理解を深め、自身の健康を守るための準備を怠らないことが求められます。 |